Application of efgartigimod in Chinese patients with myasthenia gravis: a single-center real-world prospective study

作者
Geke Zhu,Han Zhou,Wanying Wang,Yongbo Ma,Xiangtao Nie,Wenjing Qi,Lei Hao,Xiuming Guo
出处
期刊:Therapeutic Advances in Neurological Disorders [SAGE Publishing]
卷期号:18: 17562864241311127-17562864241311127 被引量:12
标识
DOI:10.1177/17562864241311127
摘要

Background: China has a large number of myasthenia gravis (MG) patients, creating an urgent need for rapid and tolerable treatment options. As the first-approved Fc receptor antagonist, efgartigimod has bright prospects for treating MG. However, real-world evidence on its application within the Chinese MG population are limited. Objective: This study aims to evaluate the rapid efficacy and safety of efgartigimod in Chinese MG population. Design: This single-center prospective study enrolled Chinese MG patients aged 18 and older who were treated with efgartigimod, classified as Myasthenia Gravis Foundation of America I-IV, with a baseline Myasthenia Gravis Activities of Daily Living (MG-ADL) score of at least 4. Methods: Patients received efgartigimod at a dose of 10 mg/kg infused once weekly for 4 weeks. During the treatment, the corticosteroids dosage could be adjusted as appropriate or the non-steroidal immunosuppressive therapies (NSISTs) added. Prior to each infusion, patients' MG-ADL scores, IgG levels, and routine laboratory tests were evaluated, while also recording the prednisone tapering and any adverse events occurring during the treatment. Results: Twenty five Chinese MG patients were enrolled between November 2023 and June 2024, including 3 with ocular MG (OMG) and 22 with generalized MG (GMG). During the 8-week follow-up, in GMG patients, whether positive for acetylcholine receptor (AChR) or muscle-specific tyrosine kinase (MuSK) antibodies, the overall efficacy was significant. Within one treatment cycle, 18 (82%) patients showed a reduction of at least 2 points in MG-ADL scores and sustained for at least 4 weeks, and 6 (27%) attained minimal symptom expression (MSE) and sustained for at least 4 weeks. Only 1 patient experienced exacerbation. Among OMG patients, 1 achieved MSE within the treatment cycle, while 2 showed minor improvements. Patients who added tacrolimus concurrently with efgartigimod did not achieve better improvement in MG-ADL scores compared to others. The average reduction in prednisone dosage was 27.4%. Only one patient experienced transient vomiting and diarrhea, with no serious adverse reactions reported. Conclusion: This study confirmed the short-term efficacy and safety of efgartigimod in Chinese MG patients. However, in clinical practice, careful consideration is needed regarding its application in OMG and whether to add NSISTs regimen during the treatment. Efgartigimod could potentially serve as an alternative to long-term corticosteroids therapy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yunfan完成签到,获得积分10
刚刚
728完成签到,获得积分10
2秒前
xhtnt97完成签到 ,获得积分10
2秒前
吉吉国王完成签到,获得积分10
2秒前
开朗大雁完成签到 ,获得积分10
3秒前
笑对人生完成签到 ,获得积分10
3秒前
11完成签到,获得积分10
4秒前
Antonio完成签到 ,获得积分0
4秒前
Only完成签到 ,获得积分10
4秒前
高石完成签到 ,获得积分10
4秒前
Thesimp完成签到 ,获得积分10
5秒前
果果完成签到 ,获得积分10
6秒前
7秒前
7秒前
零点完成签到,获得积分10
7秒前
8秒前
易玟完成签到,获得积分10
9秒前
lkd完成签到,获得积分10
10秒前
dd完成签到 ,获得积分10
10秒前
兴在路上完成签到,获得积分10
12秒前
lili完成签到,获得积分10
12秒前
12秒前
cenjin完成签到 ,获得积分10
13秒前
圆红完成签到 ,获得积分10
13秒前
文质彬彬的杨过完成签到,获得积分10
14秒前
落落完成签到 ,获得积分10
14秒前
暗中讨饭完成签到,获得积分10
14秒前
喜悦兔子完成签到 ,获得积分10
17秒前
开朗姝发布了新的文献求助10
18秒前
苗苗完成签到,获得积分10
18秒前
qin完成签到,获得积分10
18秒前
hahasun完成签到,获得积分10
18秒前
专一的幻莲完成签到,获得积分10
18秒前
Aoia完成签到,获得积分10
20秒前
苏逸完成签到,获得积分10
21秒前
Lunar完成签到 ,获得积分10
21秒前
某某完成签到,获得积分10
22秒前
dearwu完成签到,获得积分10
22秒前
潇潇完成签到 ,获得积分10
23秒前
rh完成签到,获得积分10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166570
求助须知:如何正确求助?哪些是违规求助? 9559581
关于积分的说明 21750904
捐赠科研通 7757397
什么是DOI,文献DOI怎么找? 3429170
关于科研通互助平台的介绍 2553530
邀请新用户注册赠送积分活动 2473923